Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human papillomavirus vaccination in immigrants and descendants of immigrants in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christian Dehlendorff
  • Pär Sparén
  • Birgitte Baldur-Felskov
  • Eva Herweijer
  • Lisen Arnheim-Dahlström
  • Alexander Ploner
  • Ingrid Uhnoo
  • Susanne K Kjaer
Vis graf over relationer

BACKGROUND: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination against CIN2 or worse (CIN2+), by age at vaccination, number of doses, and to test whether optimal timing of 2 doses of qHPV vaccine can confer the same level of protection as the originally recommended three dose-schedule.

METHODS: A population-based cohort of all women aged 13-30 years, living in Denmark or Sweden during 2006-2013, was followed for qHPV vaccination status and first occurrence of CIN2+.

RESULTS: The study cohort comprised 2,253,561 women, of which 33% were vaccinated during follow-up, and 1.7% were diagnosed with CIN2+. Vaccination at ages 13-16 and 17-19 was associated with a reduced risk of CIN2+ after 3 doses (IRR = 0.23, 95% CI 0.11-0.49, and IRR = 0.65, 95% CI 0.41-1.03, respectively), compared to being unvaccinated. After 1 and 2 doses there was a reduced risk, but not statistically significant. Women vaccinated ages 13-16 with 2 doses, where time between first and second dose was 5 months or longer showed no difference in risk compared to 3 doses.

CONCLUSIONS: Women vaccinated with 3 doses of qHPV showed a reduced risk of CIN2+ if they were vaccinated before age 20, with a further reduced risk if vaccinated before age 17. Vaccination with 2 doses, with the second dose 5 months or longer after the first dose, did not yield an increased risk of CIN2+, compared to 3 doses.

OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind36
Udgave nummer43
Sider (fra-til)6373-6378
Antal sider6
ISSN0264-410X
DOI
StatusUdgivet - 15 okt. 2018

ID: 56088884